Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587123 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL2495176 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| Hydrochloric Acid SCHEMBL6584130 | 0.99 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL2300523 | 0.94 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL6586600 | 0.94 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL2185913 | 0.94 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL6588021 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL3358944 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL6857856 | 0.88 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNA3CHRNB4UCHL1 | |
| SCHEMBL1241249 | 0.87 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885CHRNA3 6/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | CHRNB2 1135/4885CHRNA4 2935/4885CHRNA3 1408/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885CHRNA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.